Total Payments
$4,360
2024 Payments
$406.22
Companies
35
Transactions
271
Medicare Patients
510
Medicare Billing
$36,290
Payment Breakdown by Category
Food & Beverage$4,349 (99.8%)
Education$10.52 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,349 | 270 | 99.8% |
| Education | $10.52 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $958.76 | 63 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $461.15 | 28 | $0 (2021) |
| Astellas Pharma US Inc | $271.34 | 12 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $264.11 | 18 | $0 (2020) |
| Bayer Healthcare Pharmaceuticals Inc. | $240.97 | 14 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $239.65 | 16 | $0 (2024) |
| Lilly USA, LLC | $228.97 | 21 | $0 (2024) |
| GlaxoSmithKline, LLC. | $177.48 | 12 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $168.21 | 13 | $0 (2018) |
| PFIZER INC. | $167.92 | 12 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $406.22 | 12 | Astellas Pharma US Inc ($133.03) |
| 2023 | $411.93 | 21 | Dexcom, Inc. ($96.34) |
| 2022 | $697.29 | 39 | Novo Nordisk Inc ($235.65) |
| 2021 | $287.89 | 18 | Novo Nordisk Inc ($105.75) |
| 2020 | $528.02 | 38 | Novo Nordisk Inc ($126.23) |
| 2019 | $57.67 | 3 | Sunovion Pharmaceuticals Inc. ($57.67) |
| 2018 | $811.39 | 55 | Novo Nordisk Inc ($216.98) |
| 2017 | $1,159 | 85 | Janssen Pharmaceuticals, Inc ($211.05) |
All Payment Transactions
271 individual payment records from CMS Open Payments — Page 11 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/09/2017 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $14.01 | General |
| 03/07/2017 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $9.73 | General |
| Category: Diabetes | ||||||
| 03/07/2017 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $0.61 | General |
| Category: Diabetes | ||||||
| 03/06/2017 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $9.80 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 02/27/2017 | Lilly USA, LLC | TRULICITY (Drug), BASAGLAR | Food and Beverage | In-kind items and services | $8.54 | General |
| Category: Diabetes | ||||||
| 02/23/2017 | Novo Nordisk Inc | Victoza (Drug), Tresiba | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: Diabetes | ||||||
| 02/16/2017 | Lilly USA, LLC | TRULICITY (Drug), BASAGLAR | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Diabetes | ||||||
| 02/16/2017 | Lilly USA, LLC | TRULICITY (Drug), BASAGLAR | Food and Beverage | In-kind items and services | $0.63 | General |
| Category: Diabetes | ||||||
| 02/14/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/06/2017 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/02/2017 | Novo Nordisk Inc | Victoza (Drug), Tresiba | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: Diabetes | ||||||
| 02/02/2017 | Novo Nordisk Inc | Victoza (Drug), Tresiba | Food and Beverage | In-kind items and services | $0.46 | General |
| Category: Diabetes | ||||||
| 01/31/2017 | PFIZER INC. | CHANTIX (Drug), LYRICA | Food and Beverage | In-kind items and services | $10.94 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 01/26/2017 | Lilly USA, LLC | TRULICITY (Drug), BASAGLAR | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: Diabetes | ||||||
| 01/26/2017 | Lilly USA, LLC | TRULICITY (Drug), BASAGLAR | Food and Beverage | In-kind items and services | $0.43 | General |
| Category: Diabetes | ||||||
| 01/19/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug), BEVESPI AEROSPHERE | Food and Beverage | In-kind items and services | $33.49 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/19/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/17/2017 | SANOFI-AVENTIS U.S. LLC | SOLIQUA (Drug) | Food and Beverage | In-kind items and services | $11.47 | General |
| Category: DIABETES | ||||||
| 01/16/2017 | Takeda Pharmaceuticals America, Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: Central Nervous System (CNS) | ||||||
| 01/10/2017 | Astellas Pharma US Inc | Myrbetriq (Drug) | Food and Beverage | In-kind items and services | $15.96 | General |
| Category: Urology | ||||||
| 01/03/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $23.07 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 109 | 157 | $15,940 | $7,553 |
| 2022 | 7 | 142 | 208 | $21,079 | $9,501 |
| 2021 | 5 | 119 | 173 | $18,948 | $9,132 |
| 2020 | 7 | 140 | 200 | $21,380 | $10,104 |
Total Patients
510
Total Services
738
Medicare Billing
$36,290
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 46 | 54 | $6,372 | $3,255 | 51.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 39 | $4,524 | $2,369 | 52.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 12 | 14 | $1,624 | $865.76 | 53.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 12 | $2,052 | $701.00 | 34.2% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 17 | 38 | $1,368 | $361.76 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 32 | 39 | $6,669 | $3,322 | 49.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 53 | $6,148 | $2,753 | 44.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 24 | 24 | $2,832 | $1,257 | 44.4% |
| 99225 | Follow-up observation care per day, typically 25 minutes | Facility | 2022 | 14 | 18 | $2,088 | $985.67 | 47.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 13 | 14 | $1,624 | $712.68 | 43.9% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 26 | 43 | $1,548 | $412.60 | 26.7% |
| 81002 | Urinalysis, manual test | Office | 2022 | 15 | 17 | $170.00 | $58.39 | 34.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 35 | 68 | $7,774 | $3,654 | 47.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 23 | 29 | $4,866 | $2,634 | 54.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 29 | 29 | $3,580 | $1,583 | 44.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 14 | 14 | $1,652 | $940.00 | 56.9% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 18 | 33 | $1,076 | $320.43 | 29.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 38 | 84 | $9,240 | $4,842 | 52.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 28 | 33 | $4,620 | $1,906 | 41.3% |
| 99225 | Subsequent observation care, typically 25 minutes per day | Facility | 2020 | 16 | 18 | $1,890 | $1,037 | 54.9% |
| 99217 | Hospital observation care on day of discharge | Facility | 2020 | 16 | 17 | $2,380 | $972.36 | 40.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 11 | 13 | $1,505 | $727.42 | 48.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 18 | 19 | $1,425 | $464.51 | 32.6% |
| 83036 | Hemoglobin a1c level | Office | 2020 | 13 | 16 | $320.00 | $154.41 | 48.3% |
About Dr. Christopher Moore, D.O
Dr. Christopher Moore, D.O is a Hospitalist healthcare provider based in Latrobe, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2010. The National Provider Identifier (NPI) number assigned to this provider is 1942523725.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Moore, D.O has received a total of $4,360 in payments from pharmaceutical and medical device companies, with $406.22 received in 2024. These payments were reported across 271 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($4,349).
As a Medicare-enrolled provider, Moore has provided services to 510 Medicare beneficiaries, totaling 738 services with total Medicare billing of $36,290. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospitalist
- Other Specialties Family Medicine
- Location Latrobe, PA
- Active Since 03/08/2010
- Last Updated 01/02/2019
- Taxonomy Code 208M00000X
- Entity Type Individual
- NPI Number 1942523725
Products in Payments
- Ozempic (Drug) $347.75
- XARELTO (Drug) $316.87
- FARXIGA (Drug) $264.11
- Kerendia (Drug) $240.97
- XIFAXAN (Drug) $197.32
- Victoza (Drug) $189.20
- ELIQUIS (Drug) $186.48
- Rybelsus (Drug) $146.58
- INVOKANA (Drug) $144.28
- JARDIANCE (Drug) $143.72
- TRULICITY (Drug) $139.27
- Veozah (Drug) $133.03
- REZDIFFRA (Drug) $113.51
- CHANTIX (Drug) $101.95
- TOUJEO (Drug) $86.55
- DEXCOM G7 GSS (161) (Medical Supply) $81.90
- Myrbetriq (Drug) $78.84
- TRELEGY ELLIPTA (Drug) $73.45
- TRULANCE (Drug) $70.45
- Dexcom G6 Transmitter (Medical Supply) $62.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.